At 23:30 on the 3rd August 2017, the results of a phase II clinical trial investigating the use of a Glucagon-like peptide-1 receptor (GLP-1R) agonist called Exenatide (Bydureon) in Parkinson’s were published the Lancet journal website. The findings of the study were very interesting. And after years of failed trials, the Parkinson’s community finally had … Continue reading What do you do with a problem like Exenatide?